Dsc0027 16 Dravyr - nancygeiersbach18’s diary

Important Notice: The International Drugs.com database is in BETA release. This means it is still under development and may contain inaccuracies. It is a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to be appropriate or appropriate for you. Consult with your healthcare professional.

Always consult your healthcare provider to ensure the information provided.

DRAVYR is delivered by the companies of the world, the terms of the order are negotiated with the manager of GuttaFarm. Kamenetz-Podolsky, Chernihiv, Dnipro, Zaporizhia, Kremenchug, Alexandria, Berdyansk, Kyiv, Chernivtsi, Kherson, Lysychansk, Cherkasy, Pavlograd, Ternopil, Brovary, Khmelnytsky, Kamenskoye, Lviv, Uzhgorod, White Church , Kharkov, Rivne, Nikopol, Sumy, Slavyansk, Mariupol, Melitopol, Zhytomyr, Kramatorsk, Nikolaev, Kropyvnytskyi, Lutsk, Odessa, Severodonetsk, Poltava, Vinnitsa, Konstantinovka, Kryvyi Rih, Ivano-Frankivsk, other places of Ukraine.

By making an application, you can buy the original Dravir from a pharmacy. The manager will contact you and discuss the details of the order. Before you buy Dravir, coordinate with the manager all the details of the order. You can get answers to questions about DRAVYR in the Help-FAQ section or ask a manager a question.

Type of packaging and release form: dermatological cream 10 g 5% International name and active substances: Acyclovir Manufacturer: LISAPHARMA.

WARNING / CAUTION: Even though it may be rare, some people may have a problem when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs

Tell your doctor and pharmacist about all of your drugs (prescription OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take acyclovir with all of your drugs and health problems. Do not start, stop, or change the dose of any drug.

Use as you have been told, even if your signs get better. Do not take acyclovir cream by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn). Wash your hands before and after use. Clean affected part before use. Make sure to dry well. Put a thin layer on the skin and rub gently. Use at the first sign of a cold sore. Avoid putting on healthy skin. Do not rub the cold sore. Rubbing the cold can make it worse. It can also cause the cold to spread to other areas around the mouth.

You may report side effects to the FDA at 1-800-FDA-1088. You may also report back at http://www.fda.gov/medwatch.

Dravyr is a farmac based in the Principia attivo Aciclovir, belongen alla categoria degli Antivirali e nello specifico Antivirali. E 'commercializzato in Italia dall'azienda Lab. It. Biochim. Farm.co Lisapharma S.p.A. .

It Probenecid aumenta the media emivita e area sotto the curva delle plasma concentrazioni dell'Acyclovir. Tuttavia, nella pratica clinica, not if its osservate interacts with Acyclovir. No sono state identificate .

Source of information: Drugbank (External Link). Last updated on: 3 rd July 18 * HSA-registered product may not be HSA-registered product.

Aciclovir (INN) or acyclovir (USAN, form BAN) is a synthetic deoxyguanosine analog and it is the antiviral agent that is activated by viral thymidine kinase. The selective activity of acyclovir is due to its affinity for the enzyme thymidine kinase encoded by HSV and VZV. EC50 value of acyclovir against clinical herpes virus isolates was 1.3 μM (range: Absorption:

Hepatic Acyclovir is metabolized to 9 - [(carboxymethoxy) methyl] guanine (CMMG) and 8 hydroxy-acyclovir (8-OH-ACV) by oxidation and hydroxylation. It is suggested that acyclovir is first metabolized to acyclovir aldehyde by alcohol dehydrogenase and then converted to CMMG. The build up of acyclovir aldehyde may be the cause of acyclovir-induced nephrotoxicity in the absence of crystalluria.

A guanosine analog antiviral drug that acts as an antimetabolite. Aciclovir is used for the treatment of herpes simplex virus infections, varicella zoster (chickenpox) and herpes zoster (shingles). Aciclovir has also been investigated for the treatment of herpes labialis applied using an iontophoretic device. Currently approved drugs for the treatment of herpes labialis (cold sores). Low levels of efficacy due to the limited ability of the skin to the site where the herpes virus is replicating. Iontophoresis uses to improve the delivery of drugs through the skin.

Take Aciclovir by mouth with or without food. Start therapy with Aciclovir at the earliest sign or symptom of shingles or genital herpes (bread, burning, blisters). If treating an outbreak, continue using Aciclovir for the full course of treatment even if you feel better in a few days. For suppressive therapy, Aciclovir works best if it is taken at the same time each day. If you miss a dose of Aciclovir, take it as soon as possible. If it is almost time for your next dose, skip the dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Herpes Simplex: Short-Term Administration: The most frequent adverse events reported during clinical trials of genital herpes with Zovirax 200 mg administered orally 5 times daily every 4 hours for 10 days were nausea and / or vomiting in 8 of 298 patient treatments ( 2.7%). Nausea and / or vomiting occurred in 2 of 287 (0.7%) patients who received placebo. Long-Term Administration: The most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of 400 mg (two 200-mg capsules) 2 times daily for 1 year in 586 patients treated with Zovirax were nausea (4.8% and diarrhea (2.4%). The 589 control patients receiving intermittent treatment of recurrences with Zovirax for 1 year reported diarrhea (2.7%), nausea (2.4%), and headache (2.2%). Herpes Zoster: The most frequent adverse event reported during 3 clinical trials of herpes zoster (shingles) with 800 mg of oral Zovirax 5 times daily for 7 to 10 days in 323 patients was malaise (11.5%). The 323 placebo containers reported malaise (11.1%). Chickenpox: The most frequent adverse event reported during 3 clinical trials of oral Zovirax at doses of 10 to 20 mg / kg 4 times daily for 5 to 7 days or 800 mg 4 times daily for 5 days in 495 patients was diarrhea (3.2%). The 498 patients receiving placebo reported diarrhea (2.2%). Observed During Clinical Practice: The following events have been identified during post-approval use of Zovirax. Because they are reported voluntarily from a population of unknown size, estimates of frequency can not be made. These events have been chosen for inclusion in their seriousness, frequency of reporting, potential causal connection to Zovirax, or a combination of these factors. General: Anaphylaxis, angioedema, fever, headache, bread, peripheral edema. Nervous: Aggressive behavior, agitation, ataxia, coma, confusion, decreased consciousness, delirium, dizziness, dysarthria, encephalopathy, hallucinations, paresthesia, psychosis, seizure, somnolence, tremors. These symptoms may be marked, particularly in patients with renal impairment. Digestive: Diarrhea, gastrointestinal distress, nausea. Hematologic and Lymphatic: Anemia, leukocytoclastic vasculitis, leukopenia, lymphadenopathy, thrombocytopenia. Hepatobiliary Tract and Pancreas: Elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice. Musculoskeletal: Myalgia. Skin: Alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria. Special Senses: Visual abnormalities. Urogenital: Renal failure, renal pain, elevated blood urea nitrogen, elevated creatinine, hematuria.

Drug Interactions: coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced.

The oral bioavailability is 10% to 20%, and decreases with increasing dose. Food does not affect the absorption of acyclovir. The following are the pharmacokinetic parameters for 50 mg oral tablet, Sitavig, in the saliva: AUC 0 - 24 hours = 2900 ± 2400 mcg.h / mL; C max = 440 ± 241 mcg / mL; Tmax = 7.95 ± 4.08 hours.

DRAVYR CREAM 5% was registered with the Health Science Authority of Singapore by ZYFAS MEDICAL CO. It is marketed with the registration number of SIN08338P with effective from 1995-05-09.